Trivitron forms joint association with Japan-based Shimadzu Corporation

Labsystems Diagnostics, Helsinki, an enterprise of Chennai-based Trivitron Healthcare, entered into a joint association with Japan's Shimadzu Corporation, a leading company in analytical instruments, for clinical diagnostics in the area of newborn screening (NBS).

Financial details were not disclosed immediately.

NBS is a preventive paediatric screening service to assess the occurrence of genetic metabolic disorders. These disorders could lead to permanent neurological, cognitive, and physical damage in the child.

The companies will cooperate to leverage Labsystems' reagent technology leadership and Shimadzu's world class instrumentation to enable their global customer base to detect more disorders in newborns, more rapidly and with greater accuracy.

Further, Labsystems announced the availability of its new generation NeoMass AAAC assay, fully validated on Shimadzu's mass spectrometry platforms.

"Our alliance with Shimadzu will enable us to develop unparallelled integrated solutions for NBS, of which NeoMass AACC is only the start. Co-development on this level allows us to leverage the impressive technology leadership of Shimadzu instrumentation to provide sensitivity to new disorders, and to provide faster throughput and greater accuracy, which is the key to investigators' success in detecting disorders in babies. We believe our cooperation will have an impact on the suffering caused by these severe, yet eminently preventable diseases," said the company in a statement.

Dr Geraldine Carrard, CEO of Labsystems Diagnostics Oy, added, “The deliberations and discussions have paved the way of a trusted and solid partnership. Shimadzu, Trivitron Labsystems Diagnostics combination will be an innovative driving force to reckon within newborn screening.”